Description
Product Usage Information
Western Blotting: 1:1000
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting
Specificity / Sensitivity
GARP/LRRC32 (E2L6B) Rabbit Monoclonal Antibody recognizes endogenous levels of total GARP/LRRC32 protein. This antibody cross-reacts with an unidentified protein of 32 kDa in some cell extracts.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala292 of human GARP/LRRC32 protein.
Background
Leucine-rich repeat containing 32 (LRRC32), also known as glycoprotein A repetitions predominant (GARP), is a key regulator of the TGF-beta family (TGF-β1, TGF-β2, and TGF-β3), and is primarily expressed on the surface of mesenchymal stromal cells, hepatic stellate cells, platelets, and regulatory T cells (Tregs) (1). GARP/LRRC32 enhances the suppressive function of Tregs and decreases the expression of inflammatory cytokines, IL-2, and IFNγ (2,3). GARP/LRRC32 associates via disulfide bonds with the latency-associated peptide (LAP), the regulatory chain of TGF-β, to induce integrin-dependent activation of TGF-β and secretion (1, 3-5), thereby promoting Treg function and homeostasis. As a result, targeting GARP/LRRC32 in combination with other molecules for depleting Tregs or attenuating their suppressive activity represents an opportunity for cancer immunotherapy (6,7).
Alternate Names
D11S833E; GARP; Garpin; Glycoprotein A repetitions predominant; leucine rich repeat containing 32; Leucine-rich repeat-containing protein 32; LRC32; LRRC32; Transforming growth factor beta activator LRRC32
